Spero Q3 net loss widens to $17.1M; SPR720 halted after Phase 2a miss

Spero Therapeutics, Inc.

2024-Q3 EPS reported -$0.89 revenue$32,933,000

Q3 net loss of $17.1M ($0.32 EPS) vs $3.2M loss a year ago; revenue fell 47% to $13.5M.
Phase 3 PIVOT-PO trial of tebipenem HBr on track to complete enrollment in 2H 2025 (target ~2,648 patients).
SPR720 program suspended after Phase 2a missed primary endpoint; three cases of reversible grade 3 hepatotoxicity.
Cash and equivalents $76.3M; Oct 2024 restructuring and ~39% RIF extend cash runway into mid-2026.
SPR206 IND cleared for Phase 2 in HABP/VABP, but initiation contingent on non-dilutive funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.